Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment

Haematologica. 1999 Jun:84 Suppl EHA-4:94-5.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm / therapeutic use
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Bone Marrow Transplantation
  • Clinical Trials as Topic
  • Forecasting
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / classification
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Remission Induction
  • Rituximab
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Alemtuzumab
  • Rituximab
  • Vidarabine
  • fludarabine